Suppr超能文献

EBNA1:致癌活性、免疫逃逸及生化功能为针对爱泼斯坦-巴尔病毒相关癌症的新型治疗策略提供靶点。

EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers.

作者信息

Wilson Joanna B, Manet Evelyne, Gruffat Henri, Busson Pierre, Blondel Marc, Fahraeus Robin

机构信息

School of Life Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

CIRI, Centre International de Recherche en Infectiologie, Team Oncogenic Herpesviruses, Inserm, Université Claude Bernard Lyon 1, CNRS, ENS-Lyon, Université de Lyon, F-69007 Lyon, France.

出版信息

Cancers (Basel). 2018 Apr 6;10(4):109. doi: 10.3390/cancers10040109.

Abstract

The presence of the Epstein-Barr virus (EBV)-encoded nuclear antigen-1 (EBNA1) protein in all EBV-carrying tumours constitutes a marker that distinguishes the virus-associated cancer cells from normal cells and thereby offers opportunities for targeted therapeutic intervention. EBNA1 is essential for viral genome maintenance and also for controlling viral gene expression and without EBNA1, the virus cannot persist. EBNA1 itself has been linked to cell transformation but the underlying mechanism of its oncogenic activity has been unclear. However, recent data are starting to shed light on its growth-promoting pathways, suggesting that targeting EBNA1 can have a direct growth suppressing effect. In order to carry out its tasks, EBNA1 interacts with cellular factors and these interactions are potential therapeutic targets, where the aim would be to cripple the virus and thereby rid the tumour cells of any oncogenic activity related to the virus. Another strategy to target EBNA1 is to interfere with its expression. Controlling the rate of EBNA1 synthesis is critical for the virus to maintain a sufficient level to support viral functions, while at the same time, restricting expression is equally important to prevent the immune system from detecting and destroying EBNA1-positive cells. To achieve this balance EBNA1 has evolved a unique repeat sequence of glycines and alanines that controls its own rate of mRNA translation. As the underlying molecular mechanisms for how this repeat suppresses its own rate of synthesis in are starting to be better understood, new therapeutic strategies are emerging that aim to modulate the translation of the EBNA1 mRNA. If translation is induced, it could increase the amount of EBNA1-derived antigenic peptides that are presented to the major histocompatibility (MHC) class I pathway and thus, make EBV-carrying cancers better targets for the immune system. If translation is further suppressed, this would provide another means to cripple the virus.

摘要

在所有携带爱泼斯坦 - 巴尔病毒(EBV)的肿瘤中,EBV编码的核抗原1(EBNA1)蛋白的存在构成了一种标志物,可将病毒相关癌细胞与正常细胞区分开来,从而为靶向治疗干预提供了机会。EBNA1对于病毒基因组的维持以及控制病毒基因表达至关重要,没有EBNA1,病毒就无法持续存在。EBNA1本身与细胞转化有关,但其致癌活性的潜在机制尚不清楚。然而,最近的数据开始揭示其促进生长的途径,表明靶向EBNA1可产生直接的生长抑制作用。为了执行其任务,EBNA1与细胞因子相互作用,这些相互作用是潜在的治疗靶点,目标是削弱病毒,从而消除肿瘤细胞中与病毒相关的任何致癌活性。另一种靶向EBNA1的策略是干扰其表达。控制EBNA1的合成速率对于病毒维持足够水平以支持病毒功能至关重要,同时,限制其表达对于防止免疫系统检测和破坏EBNA1阳性细胞同样重要。为了实现这种平衡,EBNA1进化出了独特的甘氨酸和丙氨酸重复序列,该序列控制其自身mRNA的翻译速率。随着人们对该重复序列如何在体内抑制其自身合成速率的潜在分子机制开始有了更好的理解,旨在调节EBNA1 mRNA翻译的新治疗策略正在出现。如果诱导翻译,可能会增加呈递给主要组织相容性复合体(MHC)I类途径的EBNA1衍生抗原肽的数量,从而使携带EBV的癌症成为免疫系统更好的攻击目标。如果进一步抑制翻译,这将提供另一种削弱病毒的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e59a/5923364/901fc8f14f57/cancers-10-00109-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验